During this period, the team pursued additional medicinal chemistry and advanced assay work to further characterize the lead PHGDH inhibitors. This work led to a publication in Nature Chemical Biology. As a center, the NCGC has fostered and maintained over 110 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
|Pacold, Michael E; Brimacombe, Kyle R; Chan, Sze Ham et al. (2016) Corrigendum: A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nat Chem Biol 12:656|
|Pacold, Michael E; Brimacombe, Kyle R; Chan, Sze Ham et al. (2016) A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nat Chem Biol 12:452-8|